- Q3 2026 net loss was $4.1M ($0.04/share) compared to $4.9M ($0.06/share) in Q3 2025.
- Total operating expenses rose to $7.38M, partly offset by $2.97M in grant income.
- Filing includes Item 3.01, indicating non-compliance with Nasdaq continued listing rules.
Signal #143374 · SEC 8-K
$CGTX SEC Filing Alert & Real-Time AI Stock Impact Analysis
Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).
FAQ: $CGTX filing catalyst
Why did $CGTX trigger an AI stock catalyst alert?
$CGTX triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: -3.5/10). Headline: Cognition Therapeutics Reports Q3 Net Loss of $4.1M and Files Item 3.01 Delisting Notice. Key points: - Q3 2026 net loss was $4.1M ($0.04/share) compared to $4.9M ($0.06/share) in Q3 2025. - Total operating expenses rose to $7.38M, partly offset by $2.97M in grant income. - Filing includes Item 3.01, indicating non-compliance with Nasdaq continued listing rules.
How did $CGTX stock react after the SEC filing?
After the SEC 8-K for $CGTX, observed market reaction: T0 price $0.68. Past moves do not guarantee future results.
Where can I get real-time $CGTX SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $CGTX via Telegram and the VIP Web Terminal from €10/month.